Enhancing photodynamyc therapy efficacy by combination therapy: Dated, current and oncoming strategies

Cancers

Volumn 3, Issue 2, 2011, Pages 2597-2629

  Postiglione, Ilaria ^a   Chiaviello, Angela ^a   Palumbo, Giuseppe ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Combination therapy; Photodynamic therapy; Photosensitizers; Targeted therapy

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ALPHA TOCOPHEROL; AMINOLEVULINIC ACID; ASCORBIC ACID; BENZOPORPHYRIN DERIVATIVE; BUTYLATED HYDROXYANISOLE; CARBOPLATIN; CISPLATIN; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; ETOPOSIDE; GEMCITABINE; HEMATOPORPHYRIN; INDOCYANINE GREEN; METHOTREXATE; MITOMYCIN C; MYELOPEROXIDASE; PACLITAXEL; PHEOPHORBIDE; PHOTOFRIN; TEMOPORFIN; TETRAKIS(3 HYDROXYPHENYL)CHLORIN; TETRAKIS(4 SULFOPHENYL)PORPHINE; TETRASULFOPHTHALOCYANINE ALUMINUM; TROLOX C; UNINDEXED DRUG; VERTEPORFIN; VINBLASTINE; VINCRISTINE;

ACTINIC KERATOSIS; ADOPTIVE IMMUNOTHERAPY; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; BARRETT ESOPHAGUS; BASAL CELL CARCINOMA; BLADDER CANCER; BREAST ADENOCARCINOMA; BREAST CANCER; BRONCHUS CANCER; CANCER CELL CULTURE; CANCER RADIOTHERAPY; COLON CARCINOMA; DIGESTIVE SYSTEM CANCER; DRUG POTENTIATION; DRUG TARGETING; ENZYME INHIBITION; ESOPHAGUS CANCER; FIBROSARCOMA; HEAD AND NECK CANCER; HUMAN; IMMUNOMODULATION; LIVER CELL CARCINOMA; LYMPHOMA CELL; MATHEMATICAL ANALYSIS; MEDICAL RESEARCH; OVARY CANCER; PHOTODYNAMIC THERAPY; PHOTOSENSITIZATION; PROSTATE CARCINOMA; PROTEIN EXPRESSION; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; SARCOMA CELL; SQUAMOUS CELL CARCINOMA; STOMACH CANCER; TREATMENT OUTCOME; UTERINE CERVIX CANCER;

EID: 79959753142     PISSN: None     EISSN: 20726694     Source Type: Journal    
DOI: 10.3390/cancers3022597     Document Type: Review

References (168)

1. Dougherty, T.J. An update on photodynamic therapy applications. J. Clin. Laser Med. Surg. 2002, 20, 3-7.
2. Foote, C.S. Definition of type I and type II photosensitized oxidation. Photochem. Photobiol. 1991, 54, 659-672.
3. Hatz, S.; Lambert, J.D.; Ogilby, P.R. Measuring the lifetime of singlet oxygen in a single cell: Addressing the issue of cell viability. Photochem. Photobiol. Sci. 2007, 6, 1106-1116.
4. Niedre, M.; Patterson, M.S.; Wilson, B.C. Direct near-infrared luminescence detection of singlet oxygen generated by photodynamic therapy in cells in vitro and tissues in vivo. Photochem. Photobiol. 2002, 75, 382-391.
5. Detty, M.R.; Gibson, S.L.; Wagner, S.J. Current clinical and preclinical photosensitizers for use in photodynamic therapy. J. Med. Chem. 2004, 47, 3897-3915.
6. Castano, A.P.; Demidova, T.N.; Hamblin, M.R. Mechanisms in photodynamic therapy: Part two-Cellular signalling, cell metabolism and modes of cell death. Photodiagn. Photodyn. Ther. 2005, 2, 1-23.
7. Oleinick, N.L.; Morris, R.L.; Belichenko, I. The role of apoptosis in response to photodynamic therapy: What, where, why, and how. Photochem. Photobiol. Sci. 2002, 1, 1-21.
8. Krammer, B. Vascular effects of photodynamic therapy. Anticancer Res. 2001, 21, 4271-4277.
9. Korbelik, M. Induction of tumor immunity by photodynamic therapy. J. Clin. Laser Med. Surg. 1996, 14, 329-334.
10. van Duijnhoven, F.H.; Aalbers, R.I.; Rovers, J.P.; Terpstra, O.T.; Kuppen, P.J. The immunological consequences of photodynamic treatment of cancer, a literature review. Immunobiology 2003, 207, 105-113.
11. Canti, G.; De Simone, A.; Korbelik, M. Photodynamic therapy and the immune system in experimental oncology. Photochem. Photobiol. Sci. 2002, 1, 79-80.
12. Verma, S.; Watt, G. M.; Mai, Z.; Hasan, T. Strategies for enhanced photodynamic therapy effects. Photochem. Photobiol. 2007, 83, 996-1005.
13. Varriale, L.; Coppola, E.; Quarto, M.; Veneziani, B.M.; Palumbo, G. Molecular aspects of photodynamic therapy: Low energy pre-sensitization of hypericin-loaded human endometrial carcinoma cells enhances photo-tolerance, alters gene expression and affects the cell cycle. FEBS Lett. 2002, 512, 287-290.
14. Crescenzi, E.; Varriale, L.; Iovino, M.; Chiaviello, A.; Veneziani, B.M.; Palumbo, G. Photodynamic therapy with indocyanine green complements and enhances low-dose cisplatin cytotoxicity in MCF-7 breast cancer cells. Mol. Cancer Ther. 2004, 5, 537-544.
15. del Carmen, M.G.; Rizvi, I.; Chang, Y.; Moor, A.C.; Oliva, E.; Sherwood, M.; Pogue, B.; Hasan, T. Synergism of epidermal growth Factor receptor-targeted immunotherapy with photodynamic treatment of ovarian cancer in vivo. J. Natl. Cancer Inst. 2005, 20, 1516-1524.
16. Gessner, P.K. Isobolographic analysis of interactions: An update on applications and utility. Toxicology 1995, 105, 161-179.
17. Chou, T.C.; Talalay, P. Quantitative analysis of dose effect relationship: The combined effects of multiple drugs on enzyme inhibitors. Adv. Enzyme Regul. 1984, 22, 27-55.
18. Youssef, K.M.; El-Sherbeny, M.A.; El-Shafie, F.S.; Farag, H.A.; Al-Deeb, O.A.; Awadalla, S.A. Synthesis of curcumin analogues as potential antioxidant, cancer chemopreventive agents. Arch. Pharm. (Weinheim) 2004, 337, 42-54.
19. Rahman, M.A.; Amin, A.R.; Shin, D.M. Chemopreventive potential of natural compounds in head and neck cancer. Nutr. Cancer 2010, 62, 973-987.
20. Buettner, G.R.; Jurkiewicz, B.A. Catalytic metals, ascorbate and free radicals: Combinations to avoid. Radiat Res. 1996, 145, 532-541.
21. Frank, J.; Flaccus, A.; Schwarz, C.; Lambert, C.; Biesalski, H.K. Ascorbic acid suppresses cell death in rat DS-sarcoma cancer cells induced by 5-aminolevulinic acid-based photodynamic therapy. Free Radic. Biol. Med. 2006, 40, 827-836.
22. Kramarenko, G.G.; Wilke, W.W.; Dayal, D.; Buettner, G.R.; Schafer, F.Q. Ascorbate enhances the toxicity of the photodynamic action of Verteporfin in HL-60 cells. Free Radic. Biol. Med. 2006, 40, 1615-1627.
23. Shevchuk, I.; Chekulayev, V.; Chekulayeva, L. Enhancement of the efficiency of photodynamic therapy of tumors by t-butyl-4-hydroxyanisole. J. Photochem. Photobiol. 1998, 45, 136-143.
24. Melnikova, V.; Bezdetnaya, L.; Belitchenko, I.; Potapenk, A.; Merlin, J.L.; Guillemin, F. Meta-tetra(hydroxyphenyl)chlorin-sensitized photodynamic damage of cultured tumor and normal cells in the presence of high concentrations of alpha-tocopherol. Cancer Lett. 1999, 139, 89-95.
25. Melnikova, V.O.; Bezdetnaya, L.N.; Brault, D.; Potapenko, A.Y.; Guillemin, F. Enhancement of meta-tetrahydroxyphenylchlorin-sensitized photodynamic treatment on human tumor xenografts using a water-soluble vitamin E analogue, Trolox. Int. J. Cancer 2000, 88, 798-803.
26. Crul, M.; van Waardenburg, R.C.A. M.; Beijnen, J.H.; Schellens, J.H.M. DNA-based drug interactions of cis-platin. Cancer 2002, 28, 291-303.
27. Culine, S. The present and future of combination chemotherapy in bladder cancer. Semin. Oncol. 2002, 29, 32-39.
28. Rajeswaran, A.; Trojan, A.; Burnand, B.; Giannelli, M. Efficacy and side effects of cisplatin- and carboplatin-based doublet chemotherapeutic regimens versus non-platinum-based doublet chemotherapeutic regimens as first line treatment of metastatic non-small cell lung carcinoma: A systematic review of randomized controlled trials. Lung Cancer 2008, 59, 1-11.
29. Nonaka, M.; Ikeda, H.; Inokuchi, T. Effect of combined photodynamic and chemotherapeutic treatment on lymphoma cells in vitro. Cancer Lett. 2002, 184, 171-178.
30. Compagnin, C.; Mognato, M.; Celotti, L.; Canti, G.; Palumbo, G.; Reddi, E. Cell proliferation and cell cycle alterations in oesophageal p53-mutated cancer cells treated with cisplatin in combination with photodynamic therapy. Cell Prolif. 2010, 43, 262-274.
31. Lottner, C.; Knuechel, R.; Bernhardt, G.; Brunner, H. Combined chemotherapeutic and photodynamic treatment on human bladder cells by hematoporphyrin-platinum(II) conjugates. Cancer Lett. 2004, 203, 171-180.
32. He, P.; Ahn, J.C.; Shin, J.I.; Hwang, H.J.; Kang, J.W.; Lee, S.J.; Chung, P.S. Enhanced apoptotic effect of combined modality of 9-hydroxypheophorbide α-mediated photodynamic therapy and carboplatin on AMC-HN-3 human head and neck cancer cells. Oncol. Rep. 2009, 21, 329-334.
33. DiMarco, A. Adriamycin (NSC 123127): Mode and mechanism of action. Cancer Chemother. 1975, 6, 91-106.
34. Handa, K.; Sato, S. Generation of free radicals and quinine group containing anticancer chemicals in NADPH-microsome systems as evidenced by sulfite oxidation. Gann 1975, 66, 43-47.
35. Casas, A.; Fukuda, H.; Riley, P.; del C.; Batlle, A.M. Enhancement of aminolevulinic acid based photodynamic therapy by adriamycin. Cancer Lett. 1997, 121, 105-113.
36. Canti, G.; Nicolina, A.; Cubeddu, R.; Taroni, P.; Bandieramonte, G.; Valentini, G. Antitumor efficacy of the combination of photodynamic therapy and chemotherapy in murine tumors. Cancer Lett. 1998, 125, 39-44.
37. Shiah, J.G.; Sun, Y.; Peterson, C.M.; Straight, R.C.; Kopecek, J. Antitumor activity of N-(2-hydroxypropyl) methacrylamide copolymer-Mesochlorine e6 and adriamycin conjugates in combination treatments. Clin. Cancer Res. 2000, 6, 1008-1015.
38. Kirveliene, V.; Grazeliene, G.; Dabkeviciene, D.; Micke, I.; Kirvelis, D.; Juodka, B.; Didziapetriene, J. Schedule-dependent interaction between Doxorubicin and mTHPC-mediated photodynamic therapy in murine hepatoma in vitro and in vivo. Cancer Chemother. Pharmacol. 2006, 57, 65-72.
39. Khdair, A.; Chen, D.; Patil, Y.; Ma, L.; Dou, Q.P.; Shekhar, M.P.; Panyam, J. Nanoparticle-mediated combination chemotherapy and photodynamic therapy overcomes tumor drug resistance. J. Control. Release 2010, 141,137-144.
40. Szybalski, W.; Iyer, V.N. Crosslinking of DNA by enzymatic or activated mitomycins and porfiromycins, bifunctionally 'alkylating' antibiotics. Fed. Proc. 1964, 23, 946-957.
41. Ma, L.W.; Steen, H.B.; Moan, J.; Berg, K.; Peng, Q.; Saether, H.; Rimington, C. Cytotoxicity and cytokinetic effects of mitomycin C and/or photochemotherapy in a human colon adenocarcinoma cell line. Int. J. Biochem. 1992, 24, 1807-1813.
42. Ma, L.W.; Moan, J.; Berg, K.; Peng, Q.; Steen H.B. Potentiation of photodynamic therapy by mitomycin C in cultured human colon adenocarcinoma cells. Radiat. Res. 1993, 134, 22-28.
43. Baas, P.; Michielsen, C.; Oppelaar, H.; van Zandwijk, N.; Stewart, F.A. Enhancement of interstitial photodynamic therapy by mitomycin C and EO9 in a mouse tumor model. Int. J. Cancer 1994, 56, 880-885.
44. Veenhuizen, R.B.; Marijnissen, J.P.A.; Kenemans, P.; Ruevekamp-Helmers, M.C.; Mannetje, L.W.C.; Helmerhorst, Th. J.M.; Stewart, F.A. Intraperitoneal photodynamic therapy of the rat CC531 adenocarcinoma. Br. J. Cancer 1996, 73, 1387-1392.
45. van Geel, I.P.J.; Oppelaar, H.; Oussoren, Y.G.; Schuitmaker, J.J.; Stewart, F.A. Mechanisms for optimising photodynamic therapy: Second-generation photosensitisers in combination with mitomycin C. Br. J. Cancer 1995, 72, 344-350.
46. Datta, S.N.; Allman, R.; Loh, C.; Mason, M.; Matthews, P.N. Effect of photodynamic therapy in combination with mitomycin C on a mitomycin-resistant bladder cancer cell line. Br. J. Cancer 1997, 76, 312-317.
47. Skyrme, R.J.; French, A.J.; Datta, S.N.; Allman, R., Mason, M.D.; Matthews, P.N. A phase-1 study of sequential mitomycin C and 5-aminolaevulinic acid-mediated photodynamic therapy in recurrent superficial bladder carcinoma. BUJ Int. 2005, 95, 1206-1210.
48. Koh Y.; Nishio, K. Mechanisms of action of cancer chemotherapeutic agents: Topoisomerase inhibitors. In The Cancer Handbook, 1st ed.; Alison, M.R., Ed.; John Wiley & Sons: Oxford, UK, 2002.
49. Wall, M.E.; Wani, M.C.; Cook, C.E.; Palmer, K.H.; McPhail, A.I.; Sim G.A. Plant antitumor agents. I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from camptotheca acuminate. J. Am. Chem. Soc. 1966, 88, 3888-3890.
50. Adams, D.J.; Wahl, M.L; Flowers, J.L.; Sen, B.; Colvin, M.; Dewhirst, M.W.; Manikumar, G.; Wani, M.C. Camptothecin analogs with enhanced activity against human breast cancer cells. II. Impact of the tumor pH gradient. Cancer Chemother. Pharm. 2005, 57, 145-154.
51. Peng, C.L.; Lai, P.S.; Lin, F.H.; Yueh-Hsiu, W.S.; Shieh, M.J. Dual chemotherapy and photodynamic therapy in an HT-29 human colon cancer xenograft model using SN-38-loaded chlorin-core star block copolymer micelles. Biomaterials 2009, 30, 3614-3625.
52. Andoh, T.; Ishida, R. Catalytic inhibitors of DNA topoisomerase II. Biochimica et Biophysica Acta 1998, 1400, 155-171.
53. Gantchev, T.G.; Brasseur, N.; van Lier, J.E. Combination toxicity of etoposide (VP-16) and photosensitisation with a water-soluble aluminium phthalocyanine in K562 human leukaemic cells. Br. J. Cancer 1996, 74, 1570-1577.
54. Mackey, J.R.; Mani, R.S.; Selner, M.; Mowles, D.; Young, J.D.; Belt, J.A.; Crawford, C.R.; Cass, C.E. Functional nucleoside transporters are requitared for gemcitabine influx and manifestation of toxicity in cancer cell lines. Cancer Res. 1998, 58, 4349-4357.
55. Crescenzi, E.; Chiaviello, A.; Canti, G.; Reddi, E.; Veneziani, B.M.; Palumbo, G. Low doses of cisplatin or gemcitabine plus Photofrin/photodynamic therapy: Disjointed cell cycle phase-related activity accounts for synergistic outcome in metastatic non-small cell lung cancer cells (H1299). Mol. Cancer Ther. 2006, 5, 776-785.
56. Xie, Q.; Jia, L.; Liu, Y.H.; Wei, C.G. Synergetic anticancer effect of combined gemcitabine and photodynamic therapy on pancreatic cancer in vivo. World J. Gastroenterol. 2009, 15, 737-741.
57. Hatse, S.; de Clercq, E.; Balzarini, J. Role of antimetabolites of purine and pyrimidine nucleotide metabolism in tumor cell differentiation. Biochem. Pharmacol. 1999, 58, 539-555.
58. Sinha, A.K.; Anand, S.; Ortel, B.J.; Chang, Y.; Mai, Z.; Hasan, T.; Maytin, E.V. Methotrexate used in combination with aminolaevulinic acid for photodynamic killing of prostate cancer cells. Br. J. Cancer 2006, 95, 485-495.
59. Anand, S.; Honari, G.; Hasan, T.; Elson, P.; Maytin, E.V. Low-dose methotrexate enhances aminolevulinate-based photodynamic therapy in skin carcinoma cells in vitro and in vivo. Clin. Cancer Res. 2009, 15, 3333-3343.
60. Ma, L.W.; Berg, K.; Danielsen, H.E.; Kaalhus, O.; Iani, V.; Moan, J. Enhanced antitumor effect of photodynamic therapy by microtubule inhibitors. Cancer Lett. 1996, 109, 129-139.
61. Dima, V.F; Mihǎilescu, I.N.; Dima, S.V.; Chivu, L.; Stirbeţ, M., Udrea, M.; Popa, A. Studies of the effects of associated photodynamic therapy and drugs on macromolecular synthesis of tumoral cells grown in vitro. Arch. Roum. Pathol. Exp. Microbiol. 1990, 49, 155-175.
62. Lyseng-Williamson, K.A.; Fenton, C. Docetaxel: A review of its use in metastatic breast cancer. Drugs 2005, 65, 2513-2531.
63. Clarke, S.J.; Rivory, L.P. Clinical pharmacokinetics of docetaxel. Clin. Pharmacokinet. 1999, 36, 99-114.
64. Park, S.; Hong, S.P.; Oh, T.Y.; Bang, S.; Chung, J.B.; Song, S.Y. Paclitaxel augments cytotoxic effect of photodynamic therapy using verteporfin in gastric and bile duct cancer cells. Photochem. Photobiol. Sci. 2008, 7, 769-774.
65. Guo, B.; Hembruff, S.L.; Villeneuve, D.J.; Kirwan, A.F.; Parissenti, A.M. Potent killing of paclitaxel- and doxorubicin-resistant breast cancer cells by calphostin C accompanied by cytoplasmic vacuolization. Breast Cancer Res. Treat. 2003, 82, 125-141.
66. Ahmad, M.; Rees, R. C.; Ali, S. A. Escape from immunotherapy: Possible mechanisms that influence tumor regression/progression. Cancer Immunol. Immunother. 2004, 53, 844-854.
67. Zou, W. Immunosuppressive networks in the tumor environment and their therapeutic relevance. Nature Rev. Cancer 2005, 5, 263-274.
68. Kwitniewski, M.; Juzeniene, A.; Glosnicka, R.; Moan, J. Immunotherapy: A way to improve the therapeutic outcome of photodynamic therapy? Photochem. Photobiol. Sci. 2008, 7, 1011-1017.
69. Zuluaga, M.F.; Lange, N. Combination of photodynamic therapy with anti-cancer agents. Curr. Med. Chem. 2008, 15, 1655-1673.
70. Cecic, I.; Parkins, C.S.; Korbelik, M. Induction of systemic neutrophil response in mice by photodynamic therapy of solid tumors. Photochem. Photobiol. 2001, 74, 712-720.
71. de Vree, W.J.; Essers, M.C.; de Bruijn, H.S.; Star, W.M.; Koster, J.F.; Sluiter, W. Evidence for an important role of neutrophils in the efficacy of photodynamic therapy in vivo. Cancer Res. 1996, 56, 2908-2911.
72. Kousis, P.C.; Henderson, B.W.; Maier, P.G.; Gollnick, S.O. Photodynamic therapy enhancement of antitumor immunity is regulated by neutrophils. Cancer Res. 2007, 67, 10501-10510.
73. Fernandez-Varon E.; Villamayor, L. Granulocyte and granulocyte macrophage colony-stimulating factors as therapy in human and veterinary medicine. Vet. J. 2007, 174, 33-41.
74. Krosl, G.; Korbelik, M.; Krosl, J.; Dougherty, G.J. Potentiation of photodynamic therapy-elicited antitumor response by localized treatment with granulocyte-macrophage colony-stimulating factor. Cancer Res. 1996, 56, 3281-3286.
75. Golab, J.; Wilczynski, G.; Zagozdzon, R.; Stoklosa, T.; Dabrowska, A.; Rybczynska, J.; Wasik, M.; Machaj, E.; Olda, T.; Kozar, K., et al. Potentiation of the anti-tumor effects of Photofrin-based photodynamic therapy by localized treatment with G-CSF. Br. J. Cancer 2000, 82, 1485-1491.
76. Wang, H.; Wang, M.; Guo, Huang Z. Combination of immunotherapy and photodynamic therapy in the treatment of Bowenoid papulosis. Photodiagn. Photodynamic Ther. 2007, 4, 88-93.
77. Sauder, D.N. Immunomodulatory and pharmacologic properties of imiquimod. J. Am. Acad. Dermatol. 2000, 43, S6-S11.
78. Yamamoto, N.; Suyama, H.; Yamamoto, N.; Ushijima, N. Immunotherapy of metastatic breast cancer patients with vitamin Dbinding protein-derived macrophage activating factor (GcMAF). Int. J. Cancer 2008, 122, 461-467.
79. Kisker, O.; Onizuka, S.; Becker, C.M.; Fannon, M.; Flynn, E.; D'Amato, R.; Zetter, B.; Folkman, J.; Ray, R.; Swamy, N.; Pirie- Shepherd, S. Vitamin D binding protein-macrophage activating factor (DBP-maf) inhibits angiogenesis and tumor growth in mice. Neoplasia 2003, 5, 32-40.
80. Kadowaki, N.; Ho, S.; Antonenko, S.; Malefyt, R.W.; Kastelein, R.A.; Bazan, F.; Liu, Y.J. Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens. J. Exp. Med. 2001, 194, 863-869.
81. Krug, A.; Towarowski, A.; Britsch, S.; Rothenfusser, S.; Hornung, V.; Bals, R.; Giese, T.; Engelmann, H.; Endres, S., Krieg, A.M.; Hartmann, G. Toll-like receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with CD40 ligand to induce high amounts of IL-12. Eur. J. Immunol. 2001, 31, 3026-3037.
82. Supajatura, V.; Ushio, H.; Nakao, A.; Okumura, K., Ra, C.; Ogawa, H. Protective roles of mast cells against enterobacterial infection are mediated by Tolllike receptor 4. J. Immunol. 2001, 167, 2250-2256.
83. Seya, T.; Akazawa, T.; Uehori, J.; Matsumoto, M., Azuma, I.; Toyoshima, K. Role of toll-like receptors and their adaptors in adjuvant immunotherapy for cancer. Anticancer Res. 2003, 23, 4369-4376.
84. Klinman, D.M. Immunotherapeutic uses of CpG oligodeoxynucleotides. Nat. Rev. Immunol. 2004, 4, 249-258.
85. Chabalgoity, J.A.; Dougan, G.; Mastroeni P.; Aspinall, R.J. Live bacteria as the basis for immunotherapies against cancer. Expert Rev. Vaccines 2002, 1, 495-505.
86. Korbelik M.; Cooper, P.D. Potentiation of photodynamic therapy of cancer by complement: The effect of gamma-inulin. Br. J. Cancer. 2007, 96, 67-72.
87. Schroder, K.; Hertzog, P.J.; Ravasi, T. Hume, D.A. Interferongamma: An overview of signals, mechanisms and functions. J. Leuk. Biol. 2004, 75, 163-189.
88. Korbelik, M.; Sun, J.; Cecic, I.; Serrano, K. Adjuvant treatment for complement activation increases the effectiveness of photodynamic therapy of solid tumors. Photochem. Photobiol. Sci. 2004, 3, 812-816.
89. di Paola, R.; Mazzon, E.; Muia, C.; Crisafulli, C.; Genovese, T.; di Bella, P.; Esposito, E.; Menegazzi, M.; Meli, R.; Suzuki H.; Cuzzocrea, S. Protective effect of hypericum perforatum in zymosan induced multiple organ dysfunction syndrome: Relationship to its inhibitory effect on nitric oxide production and its peroxynitrite scavenging activity. Nitric Oxide 2007, 16, 118-130.
90. Myers, R.C.; Lau, B.H.; Kunihira, D.Y.; Torrey, R.R.; Woolley, J.L.; Tosk, J. Modulation of hematoporphyrin derivative-sensitized phototherapy with corynebacterium parvum in murine transitional cell carcinoma. J. Urol. 1989, 33, 230-235.
91. Korbelik, M.; Cecic, I. Enhancement of tumor response to photodynamic therapy by adjuvantmycobacterium cell-wall treatment. J. Photochem. Photobiol. B. 1998, 44, 151-158.
92. Korbelik, M.; Sun, J.; Posakony, J. J. Interaction between photodynamic therapy and BCG immunotherapy responsible for the reduced recurrence of treated mouse tumors. Photochem. Photobiol. 2001, 73, 403-409.
93. Krege, S.; Giani, G.; Meyer, R.; Otto, T.; Rubben, H.; Noll, F.; Jakse, G.; Muller, S.T.; Melchior, H.J.; Weissbach, L., et al. A randomized multicenter trial of adjuvant therapy in superficial bladder cancer: Transurethral resection only versus transurethral resection plus mitomycin C versus transurethral resection plus bacillus Calmette-Guerin. J. Urol. 1996, 156, 962-966.
94. Uehara, M.; Sano, K.; Wang, Z.L.; Sekine, J.; Ikeda H.; Inokuchi, T. Enhancement of the photodynamic antitumor effect by streptococcal preparation OK-432 in the mouse carcinoma. Cancer Immunol. Immunother. 2000, 49, 401-409.
95. Krosl, G.; Korbelik, M. Potentiation of photodynamic therapy by immunotherapy: The effect of schizophyllan (SPG). Cancer Lett. 1994, 84, 43-49.
96. Chen, W.R.; Korbelik, M.; Bartels, K.E.; Liu, H.; Sun, J.; Nordquist, R.E. Enhancement of laser cancer treatment by a chitosan-derived immunoadjuvant. Photochem. Photobiol. 2005, 81, 190-195.
97. Korbelik, M.; Naraparaju V.R.; Yamamoto, N. Macrophage directed immunotherapy as adjuvant to photodynamic therapy of cancer. Br. J. Cancer 1997, 75, 202-207.
98. North, R.J. Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells. J. Exp. Med. 1982, 155, 1063-1074.
99. Castano, A.P.; Hamblin, M.R. Anti-tumor immunity generated by photodynamic therapy in a metastatic murine tumor model. Proc. SPIE 2005, 5695, 7-16.
100. Fu, S.; Zhang, N.; Yopp, A.C.; Chen, D.; Mao, M.; Chen, D.; Zhang, H.; Ding, Y.; Bromberg, J.S. T GF-β induces Foxp3 + T-regulatory cells from CD4 + CD25- precursors. Am. J. Transplant 2004, 4, 1614-1627.
101. Wahl, S.M.; Swisher, J.; McCartney-Francis, N.; Chen, W. TGF-β: The perpetrator of immune suppression by regulatory T cells and suicidal T cells. J. Leukoc. Biol. 2004, 76, 15-24.
102. Mew, D.; Wat, C. K.; Towers, G. H.; Levy, J.G. Photoimmunotherapy: Treatment of animal tumors with tumor-specific monoclonal antibodyhematoporphyrin conjugates. J. Immunol. 1983, 130, 1473-1477.
103. Goff, B.A.; Blake, J.; Bamberg, M.P.; Hasan, T. Treatment of ovarian cancer with photodynamic therapy and immunoconjugates in a murine ovarian cancer model. Br. J. Cancer 1996, 74, 1194-1198.
104. Del Governatore, M.; Hamblin, M.R.; Shea, C.R.; Rizvi, I.; Molpus, K.G.; Tanabe, K.K.; Hasan, T. Experimental photoimmunotherapy of hepatic metastases of colorectal cancer with a 17.1A chlorin(e6) immunoconjugate. Cancer Res. 2000, 60, 4200-4205.
105. Soukos, N.S.; Hamblin, M.R.; Keel, S.; Fabian, R.L.; Deutsch, T.F.; Hasan, T. Epidermal growth factor receptor-targeted immunophotodiagnosis and photoimmunotherapy of oral precancer in vivo. Cancer Res. 2001, 61, 4490-4496.
106. Savellano, M.D.; Hasan, T. Photochemical targeting of epidermal growth factor receptor: A mechanistic study. Clin. Cancer Res. 2005, 11, 1658-1668.
107. Klein, E.; Sjogren, H.O. Humoral and cellular factors in homograft and isograft immunity. Cancer Res. 1960, 20, 452-454.
108. Old, L.J.; Boyse, E.A.; Clarke, D.A. Antigenic properties of chemically induced tumors. Ann. NY Acad. Sci. 1962, 101, 80-106.
109. Jalili, A.; Makowski, M.; Switaj, T.; Nowis, D.; Wilczynski, G.M.; Wilczek, E.; Chorazy-Massalska, M.; Radzikowska, A.; Maslinski, W.; Bialy, L., et al. Effective photoimmunotherapy of murine colon carcinoma induced by the combination of photodynamic therapy and dendritic cells. Clin. Cancer Res. 2004, 10, 4498-4508.
110. Korbelik M.; Sun, J. Cancer treatment by photodynamic therapy combined with adoptive immunotherapy using genetically altered natural killer cell line. Int. J. Cancer 2001, 93, 269-274.
111. Saji, H.; Song, W.; Furumoto, K.; Kato, H.; Engleman, E.G. Systemic antitumor effect of intratumoral injection of dendritic cells in combination with local photodynamic therapy. Clin. Cancer Res. 2006, 12, 2568-2574.
112. Korbelik, M.; Dougherty, G.J. Photodynamic therapy-mediated immune response against subcutaneous mouse tumors. Cancer Res. 1999, 59, 1941-1946.
113. Ferrario, A.; von Tiehl, K.F.; Rucker, N.; Schwarz, M.A.; Gill, P.S.; Gomer, C.J. Antiangiogenic treatment enhances photodynamic therapy responsiveness in a mouse mammary carcinoma. Cancer Res. 2000, 60, 4066-4069.
114. Ferrario, A.; Von Tiehl, K.; Wong, S.; Luna, M.; Gomer, C.J. Cyclooxygenase-2 inhibitor treatment enhances photodynamic therapy-mediated tumor response. Cancer Res. 2002, 62, 3956-3961.
115. Zuluaga, M.F.; Mailhos, C.; Robinson, G.; Shima, D.T.; Gurny, R.; Lange, N. Synergies of VEGF inhibition and photodynamic therapy in the treatment of age-related macular degeneration. Invest. Ophth. Vis. Sci. 2007, 48, 1767-1772.
116. Ferrario, A. and Gomer, C.J. Avastin enhances photodynamic therapy treatment of Kaposi's sarcoma in a mouse tumor model. J. Environ. Pathol. Toxicol. Oncol. 2006, 25, 251-259.
117. Bhuvaneswari, R.; Yuen, G.Y.; Chee, S.K.; Olivo, M. Hypericinmediated photodynamic therapy in combination with Avastin (bevacizumab) improves tumor response by downregulating angiogenic proteins. Photochem. Photobiol. Sci. 2007, 6, 1275-1283.
118. Jiang, F.; Zhang, X.; Kalkanis, S.N., Zhang, Z.; Yang, H.; Katakowski, M.; Hong, X.; Zheng, X.; Zhu, Z.; Chopp, M. Combination therapy with antiangiogenic treatment and photodynamic therapy for the nude mouse bearing U87 glioblastoma. Photochem. Photobiol. 2008, 84, 128-137.
119. Volanti, C.; Hendrickx, N.; Van Lint, J.; Matroule, J.Y.; Agostinis, P.; Piette, J. Distinct transduction mechanisms of cyclooxygenase 2 gene activation in tumour cells after photodynamic therapy. Oncogene 2005, 24, 2981-2991.
120. Kinoshita, T.; Takahashi, Y.; Sakashita, T.; Inoue, H.; Tanabe, T.; Yoshimoto, T. Growth stimulation and induction of epidermal growth factor receptor by overexpression of cyclooxygenases 1 and 2 in human colon carcinoma cells. Biochim. Biophys. Acta 1999, 1438, 120-130.
121. Singh, B.; Lucci, A. Role of cyclooxygenase-2 in breast cancer. J. Surg. Res. 2002, 108, 173-179.
122. Petkova, D.K.; Clelland, C.; Ronan, J.; Pang, L.; Coulson, J.M.; Lewis, S.; Knox, A.J. Overexpression of cyclooxygenase-2 in non-small cell lung cancer. Resp. Med. 2004, 98, 164-172.
123. Ferrario, A.; Fisher, A.M.; Rucker, N.; Gomer, C.J. Celecoxib and NS-398 enhance photodynamic therapy by increasing in vitro apoptosis and decreasing in vivo inflammatory and angiogenic factors. Cancer Res. 2005, 65, 9473-9478.
124. Makowski, M.; Grzela, T.; Niderla, J.; Lazarczyk, M.; Mroz, P.; Kopee, M.; Legat, M.; Strusinska, K.; Koziak, K.; Nowis, D., et al. Inhibition of cyclooxygenase- 2 indirectly potentiates antitumor effects of photodynamic therapy in mice. Clin. Cancer Res. 2003, 9, 5417-5422.
125. Akita, Y.; Kozaki, K.; Nakagawa, A.; Saito, T.; Ito, S.; Tamada, Y.; Fujiwara, S.; Nishikawa, N.; Uchida, K.; Yoshikawa, K., et al. Cyclooxygenase-2 is a possible target of treatment approach in conjunction with photodynamic therapy for various disorders in skin and oral cavity. Br. J. Dermatol. 2004, 151, 472-480.
126. Hendrickx, N.; Volanti, C.; Moens, U.; Seternes, O.M.; de Witte, P.; Vandenheede, J.R.; Piette, J.; Agostinis, P. Up-regulation of cyclooxygenase-2 and apoptosis resistance by p38 MAPK in hypericin-mediated photodynamic therapy of human cancer cells. J. Biol. Chem. 2003, 278, 52231-52239.
127. Hendrickx, N.; Dewaele, M.; Buytaert, E.; Marsboom, G.; Janssens, S.; Boven, M.V.; Vandenheede, J.R.; de Witte, P.; Agostinis, P. Targeted inhibition of p38alpha MAPK suppresses tumor-associated endothelial cell migration in response to hypericin-based photodynamic therapy. Biochem. Biophs. Res. Commun. 2005, 337, 928-935.
128. Ferrario, A.; Chantrain, C.F.; von Tiehl, K.; Buckley, S.; Rucker, N.; Shalinsky, D.R.; Shimada, H.; DeClerck, Y.A.; Gomer, C.J. The matrix metalloproteinase inhibitor P prinomastat enhances photodynamic therapy responsiveness in a mouse tumor model. Cancer Res. 2004, 64, 2328-2332.
129. Bergers, G.; Brekken, R.; McMahon, G.; Vu, T.H.; Itoh, T.; Tamaki, K.; Tanzawa, K.; Thorpe, P.; Itohara, S.; Werb, Z.; Hanahan, D. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat. Cell Biol. 2000, 2, 737-744.
130. Joseph, W.R.; Cao, Z.; Mountjoy, K.G.; Marshall, E.S.; Baguley, B.C.; Ching, L.M. Stimulation of tumors to synthesize tumor necrosis factor-alpha in situ using 5,6-dimethylxanthenone-4-acetic acid: A novel approach to cancer therapy. Cancer Res. 1999, 59, 633-638.
131. Bellnier, D.A.; Gollnick, S.O.; Camacho, S.H.; Greco, W.R.; Cheney, R.T. Treatment with the tumor necrosis factor-alpha-inducing drug 5,6-dimethylxanthenone-4-acetic acid enhances the antitumor activity of the photodynamic therapy of RIF-1 mouse tumors. Cancer Res. 2003, 63, 7584-7590.
132. Seshadri, M.; Bellnier, D.A. The vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid improves the antitumor efficacy and shortens treatment time associated with Photochlor-sensitized photodynamic therapy in vivo. Photochem. Photobiol. 2009, 85, 50-56.
133. Dardes, R.C.; O'Reagan, R.M.; Gajdos, C.; Robinson, S.P.; Bentrem, D. Effects of a new clinically relevant antiestrogen (GW5638) related to tamoxifen on breast and endometrial cancer growth in vivo. Clin. Cancer Res. 2002, 8, 1995-2001.
134. Park, W.C.; Jordan, V.C. Selective estrogen receptor modulators (SERMs) and their roles in breast cancer prevention. Trends Mol. Med. 2002, 8, 82-88.
135. Jiang, F.; Cho, K.K.; Mikkelsen, T.; Tong, L.; Lew, Y.S.; Hochbaum, N.; Shargorodsky, J.; Chopp M. Tamoxifen increases photodynamic therapeutic response of U87 and U25ln human glioma cells. J. Neuro-Oncol. 2002, 56, 51-58.
136. Gacio, A.F.; Fernandez-Marcos, C.; Swamy, N.; Dunn, D.; Ray, R. Photodynamic cell-kill analysis of breast tumor cells with a tamoxifen-pyropheophorbide conjugate. J. Cell. Biochem. 2006, 99, 665-670.
137. Herbst, R.S.; Shin, D.M. Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: A new paradigm for cancer therapy. Cancer 2002, 94, 1593-1611.
138. Harding, J.; Burtness, B. Cetuximab: An epidermal growth factor receptor chemeric human-murine monoclonal antibody. Drugs Today (Barc) 2005, 41,107-127.
139. Vokes, E.E.; Chu, E. Anti-EGFR therapies: Clinical experience in colorectal, lung, and head and neck cancers. Oncology (Williston Park) 2006, 20, 15-25.
140. Bhuvaneswari, R.; Gan, Y.Y.; Soo, K.C.; Olivo, M. Targeting EGFR with photodynamic therapy in combination with Erbitux enhances in vivo bladder tumor response. Mol. Cancer 2009, 8, 94-98.
141. del Carmen, M.G.; Rizvi, I.; Chang, Y.; Moor, A.C.; Oliva, E.; Sherwood, M.; Pogue, B.; Hasan, T. Synergism of epidermal growth factor receptor-targeted immunotherapy with photodynamic treatment of ovarian cancer in vivo. J. Natl. Cancer Inst. 2005, 97, 1516-1524.
142. Cohen, L.; Schwartz, S. Modification of radiosensitivity by porphyrins. II Transplanted myosarcoma in mice. Cancer Res. 1966, 26, 1769-1773.
143. Bellnier, D.A.; Dougherty, T.J. Haematoporphyrin derivative photosensitization and gamma-radiation damage interaction in chinese hamster ovary fibroblasts. Int. J. Radiat. Biol. 1986, 50, 659-664.
144. Ben-Hur, E.; Kol, R.; Marko, R.; Riklis, E.; Rosenthal, I. Combined action of phthalocyanine photosensitization and gamma-radiation on mammalian cells. Int. J. Radiat. Biol.1988, 54, 21-30.
145. Schwartz, S.; Absolon, K.; Vermund, H. Some relationships of porphyrins, X-rays, and tumors. Univ. Minn. Med. Bull. 1955, 27, 1-37.
146. Schwartz, S.; Keprios, M.; Modelevsky, G.; Freyholtz, H.; Walters, R.; Larson, L. Modification of radiosensitivity by porphyrins. Studies of tumors and other systems. In Diagnosis and Therapy of Porphyrias and Lead Intoxication, Doss, M., Ed.; Springer: Berlin, Germany, 1978 pp. 227-237.
147. Berg, K.; Luksiene, Z.; Moan, J.; Ma, L.W. Combined treatment of ionizing radiation and photosensitization by 5-aminolevulinic acid-induced protoporphyrin IX. Radiat. Res. 1995, 142, 340-346.
148. Ma, L.W.; Iani, V.; Moan, J. Combination therapy: Photochemotherapy; electric current; and ionizing radiation. Different combinations studied in a WiDr human colon adenocarcinoma cell line. J. Photochem. Photobiol. 1993, 21, 149-154.
149. Luksiene, Z.; Kalvelyte, A.; Supino, R. On the combination of photodynamic therapy with ionizing radiation. J. Photochem. Photobiol. 1999, 52, 35-42.
150. Schnitzhofer, G.M.; Krammer, B. Photodynamic treatment and radiotherapy combined effect on the colony-forming ability of V79 Chinese hamster fibroblasts. Cancer Lett. 1996, 1, 93-99.
151. Allman, R.; Cowburn, P.; Mason, M. Effect of photodynamic therapy in combination with ionizing radiation on human squamous cell carcinoma cell lines of the head and neck. Br. J. Cancer 2000, 83, 655-661.
152. Sharma, P.; Farrell, T.; Patterson, M.S.; Singh, G.; Wright, J.R.; Sur, R.; Rainbow, A.J. In vitro survival of nonsmall cell lung cancer cells following combined treatment with ionizing radiation and photofrin-mediated photodynamic therapy. Photochem. Photobiol. 2009, 85, 99-106.
153. Kostron, H.; Swartz, M.R.; Miller, D.C.; Martuza, R.L. The interaction of hematoporphyrin derivative, light and ionizing radiation in a rat glioma model. Cancer 1986, 57, 964-970.
154. Nakano, A.; Watanabe, D.; Akita, Y.; Kawamura, T.; Tamada, Y.; Matsumoto, Y. Treatment efficiency of combining photodynamic therapy and ionizing radiation for Bowen's disease. J. Eur. Acad. Dermatol. Venereol. 2010, 4, 475-478.
155. Kisselev, A.F.; Goldberg, A.L. Proteasome inhibitors: From research tools to drug candidates. Chem. Biol. 2001, 8, 739-758.
156. Kumatori, A.; Tanaka, K.; Inamura, N.; Sone, S.; Ogura, T.; Matsumoto, T.; Tachikawa, T.; Shin, S.; Ichihara, A. Abnormally high expression of proteasomes in human leukemic cells. Proc. Natl. Acad. Sci. USA 1990, 87, 7071-7075.
157. Karin, M.; Cao, Y.; Greten, F.R.; Li, Z.W. NF-kB in Cancer: From Innocent Bystander to Major Culprit. Nat. Rev. Cancer 2002, 2, 301-310.
158. Palombella, V.J.; Rando, O.J.; Goldberg, A.L.; Maniatis, T. The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B. Cell 1994, 78, 773-785.
159. Chiaviello, A.; Paciello, I.; Postiglione, I.; Crescenzi, E.; Palumbo, G. Combination of photodynamic therapy with aspirin in human-derived lung adenocarcinoma cells affects proteasome activity and induces apoptosis. Cell Prolif. 2010, 43, 480-493.
160. Szokalska, A.; Makowski, M.; Nowis, D.; Wilczynski, G.M.; Kujawa, M.; Wójcik, C.; Mlynarczuk-Bialy, I.; Salwa, P.; Bil, J.; Janowska, S., et al. Proteasome inhibition potentiates antitumor effects of photodynamic therapy in mice through induction of endoplasmic reticulum stress and unfolded proteinresponse. Cancer Res. 2009, 69, 4235-4243.
161. Hannun, Y.A. and Obeid, L.M. Principles of bioactive lipid signalling: Lessons from sphingolipids. Nat. Rev. Mol. Cell Biol. 2008, 9, 139-150.
162. Separovic, D.; Bielawski, J.; Pierce, J.S.; Merchant, S.; Tarca, A.L.; Bhatti, G.; Ogretmen, B.; Korbelik M. Enhanced tumor cures after Foscan photodynamic therapy combined with the ceramide analog LCL29. Evidence from mouse squamous cell carcinomas for sphingolipids as biomarkers of treatment response. Int. J. Oncol. 2011, 38, 521-527.
163. Koon, H.; Leung, A.W.; Yue, K.K.; Mak, N.K. Photodynamic effect of curcumin on NPC/CNE2 cells. J. Environ. Pathol. Toxicol. Oncol. 2006, 25, 205-215.
164. Kalyn, R. Overview of targeted therapies in oncology. J. Oncol. Pharm. Pract. 2007, 13, 199-205.
165. Sharman, W.M.; van Lier, J.E.; Allen, C.M. Targeted photodynamic therapy via receptor mediated delivery systems. Adv. Drug Deliv. Rev. 2004, 56, 53-76.
166. Abels, C. Targeting of the vascular system of solid tumors by photodynamic therapy (PDT). Photochem. Photobiol. Sci. 2004, 3, 765-771.
167. Hongrapipat, J.; Kopeckova P.; Liu J.; Prakongpan S.; Kopecek J. Combination chemotherapy and photodynamic therapy with fab' fragment targeted hpma copolymer conjugates in human ovarian carcinoma cells. Mol. Pharm. 2008, 5, 696-709.
168. Peterson C.M.; Lu, J.M.; Gu, Z.W.; Shiah, J.G.; Lythgoe, K.; Peterson, C.A.; Straight, R.C.; Kopecek, J. Isobolographic assessment of the interaction between adriamycin and photodynamic therapy with meso-chlorin e6 monoethylene diamine in human epithelial ovarian carcinoma (OVCAR-3) in vitro. J. Soc. Gynecol. Investig. 1995, 2, 772-777.